LIDEX
LOE ApproachingNDATOPICALOINTMENT
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LIDEX by Alvogen is clinical pharmacology: mechanism of action: lidexagel® 5% gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 1971.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIDEX is a topical ointment formulation approved in 1971 as a small-molecule NDA. The specific active ingredient and therapeutic indication are not disclosed in available data. The product is a mature topical dermatologic asset currently sponsored by Alvogen.
LOE Approaching
LOE-approaching product with moderate competitive pressure (30%) indicates a mature, potentially contracting franchise with limited growth headroom.
Mechanism of Action
CLINICAL PHARMACOLOGY: Mechanism of Action: LidexaGel® 5% Gel releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers…
Worked on LIDEX at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.